Increased frequency of a subset of NK cells (mature circulating CD3− CD56dim CD16+ NK cells) with increased TIM-3 expression had also shown a correlation with clinical outcome in melanoma patients during treatment with anti-CTLA-4 blockade (326). This evidence concerns the gene CTLA4 and melanoma.